Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 13;2(21):2811-2813.
doi: 10.1182/bloodadvances.2018025197.

Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow

Céline Mazzotti  1 , Laure Buisson  1 , Sabrina Maheo  1 , Aurore Perrot  2 , Marie-Lorraine Chretien  3 , Xavier Leleu  4 , Cyrille Hulin  5 , Salomon Manier  6 , Benjamin Hébraud  1 , Murielle Roussel  1 , Laura Do Souto  1 , Michel Attal  1 , Hervé Avet-Loiseau  1 , Jill Corre  1
Affiliations

Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow

Céline Mazzotti et al. Blood Adv. .

Abstract

  1. There is no correlation between ctDNA and bone marrow for MRD by NGS using only immunoglobulin gene rearrangements in myeloma patients.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Relationship between myeloma ctDNA and bone marrow MRD. Paired bone marrow and blood samples were obtained from 37 patients during follow-up. MRD was performed using deep sequencing. r = Pearson’s correlation coefficient.
See this image and copyright information in PMC

References

    1. Richardson PG, Weller E, Lonial S, et al. . Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5):679-686. - PMC - PubMed
    1. Moreau P, Masszi T, Grzasko N, et al. ; TOURMALINE-MM1 Study Group. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621-1634. - PubMed
    1. Dimopoulos MA, Oriol A, Nahi H, et al. ; POLLUX Investigators. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319-1331. - PubMed
    1. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. ; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142-152. - PubMed
    1. Perrot A, Lauwers-Cances V, Corre J, et al. . Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma [published online ahead of print 24 September 2018]. Blood. 10.1182/blood-2018-06-858613. - DOI - PMC - PubMed

Publication types

MeSH terms